All News

PsA recommendations update at #EULAR2023 New overarching principles - should take account of safety @rheumnow https://t.co/rrZ0ViFRPs

We would think that targeted therapies would have reduced GC use in RA. Well, this is not really the case. Comaprison of GC use in 1999-2008 vs. 2009-2018 52% of patients remain on GC for>3Mo after initiation & 1/3 still continues after 2 years! @RheumNow #EULAR23 POS0309 https://t.co/dDkUJFlmEm

Here are the PsA drugs that have come to market in recent years (and what a few years it’s been) #EULAR2023 @RheumNow https://t.co/asFsHAD21y

It might not be perfect, but it’s just great to have a dynamic poster floor back #EULAR2023. The heartbeat of the meeting! (this was near the end on the last day - it’s been properly hectic throughout) @RheumNow https://t.co/jPGO5dylvg

PsA update at #EULAR2023 new mechanisms of actions since the 2019 guidelines @RheumNow https://t.co/zaieEHN6sW

What is the course of clinically suspect arthralgia in CCP+ vs neg? 781 pts, 136 got RA and sl more resolved symptoms. RA developed in both groups ACPA+ develop more rapidly - if resolution, still more MRI + vs neg. #EULAR2023 POS319 @RheumNow Diff patterns of progression

#Sjogrens has a positive RCT with Dazodalibep. Well tolerated in Phase 2 RCT - Congratulations -heading to phase 3 Primary outcome positive but not 2ndary but not powered for them @RheumNow #EULAR2023 @eular_org LB0003 #SSj https://t.co/Qt0KTaNjsR

Weather impacts outcomes in RA: myth or reality? ⛈🌦 Larger study to date 14200 weather-matched PROs Mean PtP PtF PtGA scores higher in winter Few meteorological measures significantly correlated w/ PROs, but correlations are weak @RheumNow #EULAR23 POS0325 https://t.co/7AJmbLQrPW

Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL Surveillance). Real problem: many still have shorter follow-up periods. Cancer in particular takes time. It’s great to see data now, but: *longer follow-up needed* +++ @RheumNow https://t.co/YH4fZgNQjY

REMOTRA; REMote moniToring in pReclinical Arthritis 43pts CSA 6 Mo follow up Pts acceptance and usage decrease during time (like many other studies using apps) Composite score of PROs asso w/ risk of RA (...but VPP 12%) Digital follow up of Pre-RA is not ready for clinic yet. https://t.co/o31dVEa5xt

#EULAR2023 #LB0003 It is unheard of therapies that potentially can improve Sjogren patients with high symptoms burden. Phase 2 RCT of Dazodalibep (CD40L-i) showed ESSPRI improved vs PBO. Numerical improvement in other secondary (Fatigue). Will await results in Phase 3 @RheumNow https://t.co/0NzR83apeY

Cool way to get peg uricase tolerated in #gout. ##Rapamycin nanoparticle Rx w SEL 212 a uricase -infusion reactions 3.4% - all premeds w steroids and antihistamines- some stomatitis - seemed to lower uric acid and have good tolerability LB0002 @RheumNow #EULAR2023 @eular_org https://t.co/xWzuY3Xkyw

Amazing the chatter in the room for this one. The idea that a new JAKi might genuinely outperform existing JAKi in hard-to-treat RA, without safety cost, is particularly enticing. We all want to see the paper & healthy skepticism of ph2, but watch this space #EULAR2023 @RheumNow https://t.co/jEyk8zqZN8

https://twitter.com/yuz6yusof/status/1664895728320217088

Dazodalibep is the next CD40L inhibitor being tested in Sjogren’s - we need better therapies genuinely reducing symptom burden. Nice phase 2 data analyses so far of subjective measures, and plenty will be happy if we see this kind of result in phase 3 LB0003 #EULAR2023 @RheumNow https://t.co/HYcXEzswAg

How do we improve MTX adherence? Biochemical measure of MTX adherence 37% of patients starting a biologic do not take their MTX (!) Those who do respond better to first Biologic at 6 Mo than those who don’t 37% biologic responders = non adherent POS0313 #EULAR23 @Rheumnow https://t.co/L1Mkqpg1Aj

A mono therapy study RCT of TLL-018 vs #Tofa in RA subanalyses of previous JAKi exposure have not been done. Pts could have failed #Tofacitinib & enrolled so data could be divided to determine how this group responded. Safety looked good in both Rx LB0001 @RheumNow #EULAR2023 https://t.co/4kBHxWmk0q

https://twitter.com/janetbirdope/status/1664895058120720384

#EULAR2023 #LB0001 Data from Phase 2 RCT in China showed novel therapy, TLL-018, dual JAK1/Tyk2-i showed superior response to Tofacitinib. Safety profile were similar. Interesting to see data in Phase 3. May be an option for difficult to treat Rheumatoid Arthritis @RheumNow https://t.co/Db5QhzNUC1

#EULAR2023 Before the Highlights sessions, do come along to a session on Novel Mechanism of Cell Death at 12 noon Space 3. We have great line up of speakers 👍🏽🙌🏻 https://t.co/ObcC11uxz0

What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD

DISSOLVE 1&2 SEL 212 = tolerogenic nanoparticles containing rapamycin (SEL-110) + pegadricase (SEL-037) Meets primary endpoint in 2 RCTs High dose response 56% & 46% 97% reduction in sUA Infusion reaction 4%, stomatitis 8% Anaphylaxis 4 cases @RheumNow #EULAR23 LB0002 https://t.co/21HieM7NfC

Topics

All News

Do you get our email newsletter?